Abstract:Oxidative stress promotes T . cruzi growth and development of chronic Chagas heart dysfunction. However, the literature contains gaps that must be fulfilled, largely due to variations in parasite DTU sources, cell types, mouse strains, and tools to manipulate redox status. We assessed the impact of oxidative environment on parasite burden in cardiomyoblasts and the effects of the Nrf2-inducer COPP on heart function in BALB/c mice infected with either DTU-II Y or DTU-I Colombian T . cruzi strains. Treatment with antioxidants CoPP, apocynin, resveratrol, and tempol reduced parasite burden in cardiomyoblasts H9C2 for both DTUI- and II-strains, while H 2 O 2 increased it. CoPP treatment improved electrical heart function when administered during acute stage of Y-strain infection, coinciding with an overall trend towards increased survival and reduced heart parasite burden. These beneficial effects surpassed those of trypanocidal benznidazole, implying that CoPP directly affects heart physiology. CoPP treatment had beneficial impact on heart systolic function when performed during acute and evaluated during chronic stage. No impact of CoPP on heart parasite burden, electrical, or mechanical function was observed during the chronic stage of Colombian-strain infection, despite previous demonstrations of improvement with other antioxidants. Treatment with CoPP also did not improve heart function of mice chronically infected with Y-strain. Our findings indicate that amastigote growth is responsive to changes in oxidative environment within heart cells regardless of the DTU source, but CoPP influence on heart parasite burden in vivo and heart function is mostly confined to the acute phase. The nature of the antioxidant employed, T . cruzi DTU, and the stage of disease, emerge as crucial factors to consider in heart function studies. Chagas disease, caused by Trypanosoma cruzi, can lead to serious heart complications, known as Chagas cardiomyopathy. This study investigates the role of oxidative stress on the growth of T. cruzi and the effects of antioxidants, particularly protoporphyrin cobalt (CoPP), on heart health using two distinct strains of the parasite (Y and Colombian strains). We found that CoPP and other antioxidants, including apocynin, resveratrol, and tempol, reduced parasite levels in heart cells, while oxidative stress increased it. In mice infected with the Y strain of T. cruzi, CoPP treatment during the acute phase improved heart function, reduced parasite burden, and increased survival, outperforming the standard treatment with benznidazole. However, CoPP's benefits were mostly confined to the early stages of infection. When treatment was administered during the chronic phase, it did not improve heart function or reduce parasite levels in mice infected with the Colombian strain, despite previous studies showing that other antioxidants can be beneficial in this stage. These findings suggest that the type of antioxidant and the timing of treatment are crucial in managing Chagas disease. This work underscores the potential of early antioxidant treatments like CoPP to protect heart function and prevent long-term damage, potentially offering better treatment strategies.

NSLS in-vacuum undulators and mini-beta straights

Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection

Cardiac Abnormalities in a Predictive Mouse Model of Chagas Disease

TNF blockers alone and associated with Benznidazole impact in vitro cytokine dynamics in chronic Chagas disease

Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease

Benzonidazole treatment has a beneficial effect on cells infected with the Colombian strain of Trypanosoma cruzi

Effects of Free and Nanoencapsulated Benznidazole in Acute Trypanosoma cruzi Infection: Role of Cholinergic Pathway and Redox Status

Oral Pyronaridine Tetraphosphate Reduces Tissue Presence of Parasites in a Mouse Model of Chagas Disease

The Association of Ponderal Benznidazole with its Ultra-high Diluted Formula Reduces the Toxic Effects and Allows Increasing of Dose in Dose-dependent Protocol in Mice Infected with Trypanosoma cruzi

Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi

Adipose Tissue-Derived Mesenchymal Stromal Cells Protect Mice Infected with Trypanosoma cruzi from Cardiac Damage through Modulation of Anti-parasite Immunity

Impact of gastrointestinal inoculation and benznidazole treatment on infection by Trypanosoma cruzi (Y strain, DTU TcII) in Swiss mice

Tackling the Challenges of human Chagas Disease: a Comprehensive Review of Treatment Strategies in the Chronic Phase and Emerging Therapeutic Approaches

TNF blockade aggravates experimental chronic Chagas disease cardiomyopathy

Pseudospectral method for quadrilaterals

Heart function enhancement with Nrf2-activating antioxidant in acute Y-strain Chagas disease, not in chronic Colombian or Y-strain

The effects of inflammation on connexin 43 in chronic Chagas disease cardiomyopathy

Exercise Training Reduces Inflammation and Fibrosis and Preserves Myocardial Function and Perfusion in a Model of Chronic Chagas Cardiomyopathy

Co-Exposure of Cardiomyocytes to IFN-γ and TNF-α Induces Mitochondrial Dysfunction and Nitro-Oxidative Stress: Implications for the Pathogenesis of Chronic Chagas Disease Cardiomyopathy

Association between altered tryptophan metabolism, plasma aryl hydrocarbon receptor agonists, and inflammatory Chagas disease